Chronic Immune Thrombocytopenia In Adults Therapeutics
1. Tavalisse patent expiration
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
TAVALISSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7538108 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(2 months from now) | |
| US7989448 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8163902 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8211889 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US7449458 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737554 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8951504 | RIGEL PHARMS | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(6 years from now) | |
| US8912170 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US9283238 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US9266912 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8445485 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8652492 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2028
(2 years from now) | |
| US8263122 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2030
(4 years from now) | |
| USRE48898 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8771648 | RIGEL PHARMS | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Dosage: TABLET
How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage
TAVALISSE family patents
